HQP8361

News alerts, weekly reports and conference planners

Company:

Ascentage Pharma, Merck (MSD)

Drug class:

c-MET inhibitor

Related drugs:

‹

›

MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	osimertinib + HQP8361 Sensitive: D – Preclinical osimertinib + HQP8361 Sensitive : D	osimertinib + HQP8361 Sensitive: D – Preclinical osimertinib + HQP8361 Sensitive : D
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	HQP8361 Sensitive: D – Preclinical HQP8361 Sensitive : D	HQP8361 Sensitive: D – Preclinical HQP8361 Sensitive : D

Associations
(2)